Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865887 | 0.84 | BACE1 (0.34) | KMT2ADPP8DPP9 | |
| SCHEMBL13668852 | 0.84 | BACE1 (0.34) | KMT2ADPP8DPP9 | |
| SCHEMBL13385386 | 0.84 | BACE1 (0.34) | KMT2ADPP8DPP9 | |
| SCHEMBL13646902 | 0.84 | BACE1 (0.34) | KMT2ADPP8DPP9 | |
| SCHEMBL13519923 | 0.84 | BACE1 (0.34) | KMT2ADPP8DPP9 | |
| SCHEMBL8093393 | 0.81 | MEN1 (0.38) | KMT2APOLB | |
| SCHEMBL3876093 | 0.76 | CYP3A4 (0.42) | — | |
| SCHEMBL13646901 | 0.76 | CYP3A4 (0.42) | — | |
| SCHEMBL3865888 | 0.76 | MEN1 (0.33) | KMT2APOLB | |
| SCHEMBL8238943 | 0.76 | KMT2A (0.34) | KMT2ADPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| EP-1713822-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713822-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073216-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | KMT2A 4582/4885DPP8 269/4885DPP9 384/4885 |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | KMT2A 3466/4885DPP8 409/4885DPP9 413/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | KMT2A 4573/4885DPP8 76/4885DPP9 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.